|
Bengaluru, India, May 07, 2019
Following the successful approval and European launch of Hulio®, (biosimilar Adalimumab) in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialization rights have been extended from Europe to Global Markets.
Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from Global Markets.
Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process.
- Biocon Spokesperson
| 
